These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 32404306)

  • 1. Hormone Therapy Linked to Cognitive Decline.
    Cancer Discov; 2020 Jul; 10(7):896. PubMed ID: 32404306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cognitive Impairment in Patients With Breast Cancer: Understanding the Impact of Chemotherapy and Endocrine Therapy.
    Ganz PA; Van Dyk K
    J Clin Oncol; 2020 Jun; 38(17):1871-1874. PubMed ID: 32142394
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial.
    Sparano JA; Gray RJ; Makower DF; Albain KS; Saphner TJ; Badve SS; Wagner LI; Kaklamani VG; Keane MM; Gomez HL; Reddy PS; Goggins TF; Mayer IA; Toppmeyer DL; Brufsky AM; Goetz MP; Berenberg JL; Mahalcioiu C; Desbiens C; Hayes DF; Dees EC; Geyer CE; Olson JA; Wood WC; Lively T; Paik S; Ellis MJ; Abrams J; Sledge GW
    JAMA Oncol; 2020 Mar; 6(3):367-374. PubMed ID: 31566680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fatigue and endocrine symptoms among women with early breast cancer randomized to endocrine versus chemoendocrine therapy: Results from the TAILORx patient-reported outcomes substudy.
    Garcia SF; Gray RJ; Sparano JA; Tevaarwerk AJ; Carlos RC; Yanez B; Gareen IF; Whelan TJ; Sledge GW; Cella D; Wagner LI
    Cancer; 2022 Feb; 128(3):536-546. PubMed ID: 34614209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cognitive effects of adjuvant endocrine therapy in older women treated for early-stage breast cancer: a 1-year longitudinal study.
    Underwood EA; Jerzak KJ; Lebovic G; Rochon PA; Elser C; Pritchard KI; Tierney MC
    Support Care Cancer; 2019 Aug; 27(8):3035-3043. PubMed ID: 30610433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cognitive impairment in patients with early breast cancer receiving adjuvant systemic therapy: results from a substudy of the TAILORx trial].
    Souchon R
    Strahlenther Onkol; 2020 Dec; 196(12):1142-1144. PubMed ID: 33009622
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinicopathologic analysis of 722 breast cancer patients who met the inclusion criteria of the TAILORx trial.
    Xiang HY; Liu YH; Zhang H; Zhang S; Xin L; Xu L; Ye JM; Li T; Duan XN; Liu Q
    Chin Med J (Engl); 2019 Dec; 132(24):2914-2919. PubMed ID: 31809316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endocrine treatment-associated cognitive impairment in breast cancer survivors: evidence from published studies.
    Lee PE; Tierney MC; Wu W; Pritchard KI; Rochon PA
    Breast Cancer Res Treat; 2016 Aug; 158(3):407-20. PubMed ID: 27432418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Community-based assessment of adjuvant hormone therapy in women with breast cancer, 1991-1997.
    Du XL; Key CR; Osborne C
    Breast J; 2004; 10(5):433-9. PubMed ID: 15327498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial.
    Wefel JS; Lenzi R; Theriault RL; Davis RN; Meyers CA
    Cancer; 2004 Jun; 100(11):2292-9. PubMed ID: 15160331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Self-reported cognitive decline in Japanese patients with breast cancer treated with endocrine therapy.
    Yamamoto S; Masutani E; Arao H
    Breast Cancer; 2020 Jul; 27(4):670-682. PubMed ID: 32114664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Breast cancer plus adjuvant chemotherapy- related cognitive impairment: a case study.
    Fischer B
    Neurocase; 2019; 25(3-4):138-144. PubMed ID: 31237172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deconstructing Decisions to Initiate, Maintain, or Discontinue Adjuvant Endocrine Therapy in Breast Cancer Survivors: A Mixed-Methods Study.
    Bluethmann SM; Murphy CC; Tiro JA; Mollica MA; Vernon SW; Bartholomew LK
    Oncol Nurs Forum; 2017 May; 44(3):E101-E110. PubMed ID: 28635973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Adjuvant Anthracycline-Based and Taxane-Based Chemotherapy on Plasma VEGF Levels and Cognitive Function in Breast Cancer Patients: A Longitudinal Study.
    Ng T; Phey XY; Yeo HL; Shwe M; Gan YX; Ng R; Ho HK; Chan A
    Clin Breast Cancer; 2018 Oct; 18(5):e927-e937. PubMed ID: 29705024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cognitive impairment following chemotherapy for breast cancer: The impact of practice effect on results.
    Cerulla N; Arcusa À; Navarro JB; de la Osa N; Garolera M; Enero C; Chico G; Fernández-Morales L
    J Clin Exp Neuropsychol; 2019 Apr; 41(3):290-299. PubMed ID: 30477390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cognitive function and reproductive hormones in adjuvant therapy for breast cancer: a critical review.
    Bender CM; Paraska KK; Sereika SM; Ryan CM; Berga SL
    J Pain Symptom Manage; 2001 May; 21(5):407-24. PubMed ID: 11369162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of changes in perceived attentional function on postsurgical health-related quality of life in breast cancer patients awaiting adjuvant treatment.
    Jung MS; Visovatti MA; Sohn EH; Yoo HS; Kim M; Kim JR; Lee JS
    Health Qual Life Outcomes; 2020 Jul; 18(1):230. PubMed ID: 32664976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.
    Sparano JA; Gray RJ; Makower DF; Pritchard KI; Albain KS; Hayes DF; Geyer CE; Dees EC; Goetz MP; Olson JA; Lively T; Badve SS; Saphner TJ; Wagner LI; Whelan TJ; Ellis MJ; Paik S; Wood WC; Ravdin PM; Keane MM; Gomez Moreno HL; Reddy PS; Goggins TF; Mayer IA; Brufsky AM; Toppmeyer DL; Kaklamani VG; Berenberg JL; Abrams J; Sledge GW
    N Engl J Med; 2018 Jul; 379(2):111-121. PubMed ID: 29860917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole.
    Carlson RW; Henderson IC
    Breast Cancer Res Treat; 2003; 80 Suppl 1():S19-26; discussion S27-8. PubMed ID: 14535531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beyond tamoxifen: extended and late extended endocrine therapy in postmenopausal early breast cancer.
    Dodwell D; Williamson D
    Cancer Treat Rev; 2008 Apr; 34(2):137-44. PubMed ID: 18006236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.